An open-label, multicenter, international, Phase II trial of MCLA-128 in combination with trastuzumab and chemotherapy or fulvestrant in confirmed HER2-positive Metastatic Breast Cancer patients and confirmed hormone receptor positive status and HER2-low Metastatic Breast Cancer patients progressing on hormone therapies and CDK4/6

Trial Profile

An open-label, multicenter, international, Phase II trial of MCLA-128 in combination with trastuzumab and chemotherapy or fulvestrant in confirmed HER2-positive Metastatic Breast Cancer patients and confirmed hormone receptor positive status and HER2-low Metastatic Breast Cancer patients progressing on hormone therapies and CDK4/6

Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs MCLA 128 (Primary) ; Fulvestrant; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2017 According to a Merus media release, this trial is expected to initiate in the fourth quarter of 2017.
    • 24 May 2017 New trial record
    • 17 May 2017 According to a Merus media release, this trial is expected to initiate in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top